Literature DB >> 3082492

Inhibition of secretion of rat calcitonin by calmodulin inhibitors.

C W Cooper, S A Borosky.   

Abstract

Studies were designed to investigate the potential importance of calmodulin in release of calcitonin (CT) in response to an increase in the concentration of extracellular Ca. In vitro release of CT from baby rat thyroparathyroids incubated up to 8 h was examined at normal (1 mM) and high (2.5 mM) Ca in serum-free medium in the presence and absence of the potent calmodulin inhibitors, trifluoperazine (TFP) and N-(6-aminohexyl)-5-Cl-1-naphthalene sulfonamide (W-7). The drugs chlorpromazine (CLP) and haloperidol (HAL) which, like TFP, are anti-psychotic agents also were tested. In some studies release of parathyroid hormone (PTH) into medium also was studied. At 2.5 mM Ca, CT release was increased five- tenfold compared with 1 mM Ca while PTH was suppressed by approximately 80%. The increased release of CT induced by 2.5 mM Ca was inhibited 60-90% by 10(-4) M TFP and 10(-4) M W-7, but was unaffected by 10(-4) M CLP or HAL. In the presence of 1 mM Ca, the increased release of PTH also was inhibited significantly by 10(-4) M TFP and 10(-4) M W-7. In related in vivo studies, administration of TFP i.v. to rats just before induction of hypercalcemia with i.v. CaCl2 suppressed the increase in plasma CT normally observed 3 min later in a dose-related manner. The results show that calmodulin inhibitors can inhibit in vitro secretion of CT, and release of PTH as well. Additionally, inhibition of the in vivo CT response to a Ca challenge was observed within minutes of drug administration.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3082492     DOI: 10.1007/bf02556837

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  10 in total

1.  In vitro secretion of immunoreactive rat thyrocalcitonin.

Authors:  C W Cooper; W K Ramp; D I Becker; D A Ontjes
Journal:  Endocrinology       Date:  1977-07       Impact factor: 4.736

2.  Mechanism by which psychotropic drugs inhibit adenosine cyclic 3',5'-monophosphate phosphodiesterase of brain.

Authors:  R M Levin; B Weiss
Journal:  Mol Pharmacol       Date:  1976-07       Impact factor: 4.436

3.  Selective binding of antipsychotics and other psychoactive agents to the calcium-dependent activator of cyclic nucleotide phosphodiesterase.

Authors:  R M Levin; B Weiss
Journal:  J Pharmacol Exp Ther       Date:  1979-03       Impact factor: 4.030

4.  Calmodulin activation of red blood cell (Ca2+ + Mg2+)-ATPase and its antagonism by phenothiazines.

Authors:  B U Raess; F F Vincenzi
Journal:  Mol Pharmacol       Date:  1980-09       Impact factor: 4.436

5.  Concurrent secretion of calcitonin and parathyroid hormone in vitro from the rat thyroparathyroid complex.

Authors:  C W Cooper; W K Ramp; A J Ross; S A Wells
Journal:  Proc Soc Exp Biol Med       Date:  1978-07

6.  Effects of lanthanum and trifluoperazine on [125I]calmodulin binding to rat striatal particulates.

Authors:  Y S Lau; M E Gnegy
Journal:  J Pharmacol Exp Ther       Date:  1980-10       Impact factor: 4.030

7.  Secretion of calcitonin in the genetically obese Zucker rat (fa/fa).

Authors:  C W Cooper; J F Obie; A R Hughes; D L Margules; J J Flynn
Journal:  Proc Soc Exp Biol Med       Date:  1983-05

8.  Role of calmodulin in platelet aggregation. Structure-activity relationship of calmodulin antagonists.

Authors:  M Nishikawa; H Hidaka
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

9.  Calmodulin: an overview.

Authors:  W Y Cheung
Journal:  Fed Proc       Date:  1982-05

10.  Purification, characterization and radioimmunoassay of thyrocalcitonin from rat thyroid glands.

Authors:  H J Burford; D A Ontjes; C W Cooper; A F Parlow; P F Hirsch
Journal:  Endocrinology       Date:  1975-02       Impact factor: 4.736

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.